Humacyte annual current ratio
2020
2021
2022
2023
2024
2025
Humacyte Current Ratio Growth & History (HUMA)
Humacyte's current ratio was 3.69 for fiscal 2025.
View full Humacyte company overviewHumacyte annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 3.69 | 1.29 | +53.85% |
| 2024 | 2024-12-31 | 2.40 | −2.12 | −46.88% |
| 2023 | 2023-12-31 | 4.52 | −3.36 | −42.67% |
| 2022 | 2022-12-31 | 7.88 | −12.88 | −62.05% |
| 2021 | 2021-12-31 | 20.75 | 17.06 | +462.47% |
| 2020 | 2020-12-31 | 3.69 | — | — |
Humacyte quarterly current ratio
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 6.21 | 3.75 | +153.01% |
| Q1 2026 | 2026-03-31 | 3.93 | 0.25 | +6.77% |
| Q4 2025 | 2025-12-31 | 3.69 | 1.29 | +53.85% |
| Q3 2025 | 2025-09-30 | 1.62 | 0.52 | +47.15% |
| Q2 2025 | 2025-06-30 | 2.45 | −2.96 | −54.67% |
| Q1 2025 | 2025-03-31 | 3.68 | −4.69 | −56.04% |
| Q4 2024 | 2024-12-31 | 2.40 | −2.12 | −46.88% |
| Q3 2024 | 2024-09-30 | 1.10 | −5.70 | −83.83% |
| Q2 2024 | 2024-06-30 | 5.41 | −5.17 | −48.87% |
| Q1 2024 | 2024-03-31 | 8.37 | 2.70 | +47.60% |
| Q4 2023 | 2023-12-31 | 4.52 | −3.36 | −42.67% |
| Q3 2023 | 2023-09-30 | 6.79 | −2.96 | −30.32% |
| Q2 2023 | 2023-06-30 | 10.59 | −6.87 | −39.35% |
| Q1 2023 | 2023-03-31 | 5.67 | −13.77 | −70.83% |
| Q4 2022 | 2022-12-31 | 7.88 | −12.88 | −62.05% |
| Q3 2022 | 2022-09-30 | 9.75 | −1.74 | −15.16% |
| Q2 2022 | 2022-06-30 | 17.46 | 15.35 | +729.23% |
| Q1 2022 | 2022-03-31 | 19.45 | 14.75 | +313.68% |
| Q4 2021 | 2021-12-31 | 20.75 | 17.06 | +462.47% |
| Q3 2021 | 2021-09-30 | 11.49 | 0.31 | +2.80% |
| Q2 2021 | 2021-06-30 | 2.11 | — | — |
| Q1 2021 | 2021-03-31 | 4.70 | — | — |
| Q4 2020 | 2020-12-31 | 3.69 | — | — |
| Q3 2020 | 2020-09-30 | 11.18 | — | — |
Humacyte current ratio trends
Over the last five fiscal years, Humacyte's current ratio increased from 3.69 to 3.69, a change of 0.00. The latest reported quarter, Q2 2026, shows 6.21.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Humacyte source filings ↗